Department of Internal Medicine, University of Cincinnati College of Medicine, Ohio 45267-0563, USA.
Allergy Asthma Proc. 2011 Jan-Feb;32(1):49-54. doi: 10.2500/aap.2011.32.3400.
This study was designed to determine if patients with allergic rhinitis (AR) and mixed rhinitis (MR) subtypes have similar treatment outcomes after a full course of allergen immunotherapy (AIT). A historical pre- and posttreatment study design was used to identify all AR patients in a large allergy practice who started AIT in 2001 and completed at least a 3-year course. One reviewer compiled data through chart review using a standardized form that recorded allergic and nonallergic irritant triggers, symptoms, and medication requirements before and after completion of ≥3 years of AIT. Other than age, there were no significant differences in baseline demographic characteristics, allergic triggers, or rhinitis symptoms between the AR and MR groups. Both groups experienced reduced episodes of sinusitis after AIT. Although both groups also had a significant decrease in the mean number of rhinitis medications after AIT (p < 0.001), the reduction in number of medications was significantly greater for the AR versus the MR group (1.24 ± 1.09 versus 2.09 ± 1.55; p = 0.0023). AIT is a very effective treatment for AR and MR patients. However, these data support the classification of MR as a distinct rhinitis phenotype because MR patients required significantly more medications after a full course of AIT to control their nonallergic-induced symptoms.
这项研究旨在确定过敏性鼻炎（AR）和混合性鼻炎（MR）亚类患者在接受全疗程变应原免疫治疗（AIT）后是否具有相似的治疗效果。采用历史前瞻性治疗研究设计，确定了 2001 年在一家大型过敏治疗中心开始接受 AIT 并完成至少 3 年疗程的所有 AR 患者。一名评审员使用标准化表格通过图表审查来汇编数据，该表格记录了在完成 ≥3 年 AIT 前后的过敏和非过敏刺激性诱因、症状和药物需求。除了年龄外，AR 和 MR 组在基线人口统计学特征、过敏诱因或鼻炎症状方面均无显著差异。两组患者在接受 AIT 后鼻窦炎发作次数均减少。尽管两组患者在 AIT 后平均鼻炎药物使用数量均显著减少（p < 0.001），但 AR 组的药物减少量明显大于 MR 组（1.24 ± 1.09 与 2.09 ± 1.55；p = 0.0023）。AIT 是治疗 AR 和 MR 患者的非常有效的方法。然而，这些数据支持将 MR 归类为一种独特的鼻炎表型，因为 MR 患者在完成 AIT 全疗程后需要使用更多药物来控制非过敏性诱导的症状。
